Paradigm Biocapital Advisors LP: TARSUS PHARMACEUTICALS INC (TARS): Quarterly 13F Position History
As of Q1 2026, Paradigm Biocapital Advisors LP reported 2,562,154 shares of TARSUS PHARMACEUTICALS INC (TARS), worth $179.7M and representing 3.7% of its 13F equity book. The position first appeared in Q4 2023 and has been disclosed across 10 13F-HR filings in Pactolio's tracked window.
- 2,562,154Shares Held (Latest Filing)
- $179.7MReported Market Value (Latest Filing)
- 3.7%Portfolio Weight (% of 13F Equity Book)
- 0Quarter-over-Quarter Share Change
- -$30.1MQuarter-over-Quarter Value Change
- 2,976,099Peak Reported Shares (Historical)
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 10 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q1 2026 | 2,562,154 | 0 | — | $179.7M | 3.7% | $70.2 |
| Q4 2025 | 2,562,154 | 103,544 | -3.9% | $209.8M | 5.6% | $81.9 |
| Q3 2025 | 2,665,698 | 310,401 | -10.4% | $158.4M | 4.7% | $59.4 |
| Q2 2025 | 2,976,099 | +365,902 | +14.0% | $120.6M | 5.1% | $40.5 |
| Q1 2025 | 2,610,197 | +78,301 | +3.1% | $134.1M | 6.2% | $51.4 |
| Q4 2024 | 2,531,896 | +91,451 | +3.7% | $140.2M | 4.9% | $55.4 |
| Q3 2024 | 2,440,445 | +5,029 | +0.2% | $80.3M | 2.8% | $32.9 |
| Q2 2024 | 2,435,416 | 427,990 | -14.9% | $66.2M | 2.5% | $27.2 |
| Q1 2024 | 2,863,406 | +1,838,406 | +179.4% | $104.1M | 3.7% | $36.4 |
| Q4 2023 | 1,025,000 | — | — | $20.8M | 1.0% | $20.3 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares — a quarter-end mark, not the manager's cost basis. See the full methodology document for the normalization rules.
When did Paradigm Biocapital Advisors LP first disclose a TARS position in 13F-HR filings?
Paradigm Biocapital Advisors LP first reported TARSUS PHARMACEUTICALS INC (TARS) on its 13F-HR filing for the period ending 2023-12-31 (Q4 2023). The position has appeared on 10 reported quarters within Pactolio's tracked window.
What was Paradigm Biocapital Advisors LP's most recent quarter-over-quarter share-count change in TARS?
Paradigm Biocapital Advisors LP held the same 2,562,154 shares of TARS between Q4 2025 and Q1 2026 — the reported share count was unchanged quarter-over-quarter.
Does the implied price-per-share represent Paradigm Biocapital Advisors LP's cost basis in TARS?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.